Brain+ A/S

BRAINP

DK0061670205

Software

Market Closed - Nasdaq Copenhagen Other stock markets 10:27:58 2024-04-18 am EDT			5-day change	1st Jan Change
0.1195 ^DKK	-3.63%		-14.64%	-38.40%

Feb. 09	Brain+ Teams Up with Quiddity Health to Launch Cognitive Stimulation Therapy Software in UK	MT
Feb. 09	Brain+ A/S Partners with Quiddity Health to Prepare UK Market Entry for CST-Therapist Companion	CI

Investor Update: Exercise via Nordnet of TO1 warrants possible until October 27[th] 2022

October 24, 2022 at 07:41 am EDT

Copenhagen, Denmark October 24, 2022 - Brain+ A/S (Nasdaq First North: BRAINP)

Nordnet has announced that exercise of warrants of series TO1 (the "Warrants"), which were issued in connection with the Company's IPO on Nasdaq First North Growth Market, Denmark in October 2021, will be possible for holders via their platform until October 27^th 2022.

Advisers and issuing agent
Gemstone Capital is Brain+'s financial advisor in connection with the Warrant exercise. Jyske Bank is the issuing agent.

For any questions regarding the Warrants, please contact:
Gemstone Capital
Phone: +45 27 85 54 44
E-mail: kl@gemstonecapital.com
www.gemstonecapital.com

Contact Information

CEO, Kim Baden-Kristensen + 45 31393317, E-mail: kim@brain-plus.com, Brain+ A/S, Købmagergade 53, 3.

https://news.cision.com/brain--a-s/r/investor-update--exercise-via-nordnet-of-to1-warrants-possible-until-october-27-th--2022,c3653651

https://mb.cision.com/Public/20893/3653651/b6b0c0b2068f61b9.pdf

https://news.cision.com/brain--a-s/i/1-b-en-rgb,c3104859

Latest news about Brain+ A/S

Brain+ Teams Up with Quiddity Health to Launch Cognitive Stimulation Therapy Software in UK	Feb. 09	MT
Brain+ A/S Partners with Quiddity Health to Prepare UK Market Entry for CST-Therapist Companion	Feb. 09	CI
Brain+ Bags Two Cognitive Stimulation Therapy Software Supply Deals in Denmark	Jan. 18	MT
Brain+ Signs Two New Danish Sales Contracts on CST-Therapist Companion and Updates on the Product's Commercial Potential	Jan. 18	CI
Brain+ Names Interim CFO to Permanent Role	Jan. 09	MT
Brain+ A/S Announces CFO Changes	Jan. 09	CI
Brain+ A/S Announces Resignation of Anders Härfstrand as Chairman and Member of the Board, Effective from January 31, 2024	Dec. 14	CI
Brain+ Receives DKK4 Million Grant in Denmark for Digital Therapy Platform for Dementia Support	Dec. 14	MT
Brain+ to Supply Cognitive Stimulation Therapy Software to Care Facilities in Copenhagen, Denmark	Dec. 11	MT
Brain+ A/S Closes Sales Contract with Copenhagen Municipality on CST-Therapist Companion to Support Dementia Care and Therapy	Dec. 11	CI
Brain+ Nominates to CO-PI Grant of Up to DKK 3.5 Million from Denmark's Business Promotion Board	Nov. 23	CI
Brain+ Launches Usability Study in Denmark for Cognitive Stimulation Therapy Therapist Companion Platform	Nov. 14	MT
Brain+ A/S and VIA University College start usability study on CST-Therapist Companion in Denmark	Nov. 14	CI
Brain+ A/S Announces Resignation of Betül Susamis Unaran, Member of the Board of Directors, Effective on 30 November	Nov. 02	CI
Nexstim Wins Order for Navigated Brain Stimulation System in Finland	23-10-20	MT
Brain+ A/S Releases New Version of Its Cst-Therapist Companion Dementia Product with Updated User Features	23-10-04	CI
Brain+ Secures Grant to Advance Funding Application for Dementia Therapy Project	23-09-20	MT
Brain+ Says Grant Applications Progressing for DKK67 Million in Funding	23-09-13	MT
Brain+ Wins Intellectual Property Protection for Cognitive Stimulation Therapy Product in UK, EU	23-09-08	MT
Brain+ Secures Intellectual Property Rights for CST-Therapist Companion in the Eu and the United Kingdom	23-09-08	CI
Brain+ A/S Provides Earnings Guidance for the Full Year 2023	23-08-31	CI
Brain+ Seeks Up to DKK67 Million in Public Soft Funding for Digital Dementia Therapy Product	23-08-25	MT
Brain+ to Initiate Feasibility Studies of Digital Dementia Therapy Support Product in Q4	23-08-09	MT
Brain+ A/S and Danish Municipality Are Advancing the Development of Version 2.0 of the CST Therapist Companion	23-08-09	CI
Brain+ A/S Announces Breakthrough Alzheimer's Drug Approval Seen to Renew Dementia Drug Investments and Increase the Potential for Digital Dementia Therapeutics	23-07-10	CI

Chart Brain+ A/S

Duration

Period

More charts

Company Profile

Brain+ A/S is a Denmark-based software company primarily engaged in developing medical software. The Company focuses on the development of digital treatment for dementia and Alzheimer's disease by digital therapeutics. The Company's main activities include the development of Cognitive Stimulation Therapy for the treatment of dementia, Computerized Cognitive Training for the treatment of earlier stages of Alzheimer's and Starry Night memory test for early detection and monitoring of Alzheimer's. It offers a product called Digital CST assistant giving access to Cognitive Stimulation Therapy sessions, available in Danish.

Sector

Software

More about the company

Sector Other Software

	1st Jan change	Capi.
BRAIN+ A/S	-38.40%	1.62M
MICROSOFT CORPORATION	+7.52%	3,060B
SYNOPSYS INC.	+0.93%	80.48B
CADENCE DESIGN SYSTEMS, INC.	+4.97%	80.07B
DASSAULT SYSTÈMES SE	-13.12%	53.61B
ATLASSIAN CORPORATION	-18.60%	50.6B
PALANTIR TECHNOLOGIES INC.	+23.06%	47.15B
THE TRADE DESK, INC.	+12.30%	39.16B
SEA LIMITED	+39.01%	31.53B
TAKE-TWO INTERACTIVE SOFTWARE, INC.	-12.62%	24.42B

Other Software

Brain+ A/S

Equities

BRAINP

DK0061670205

Software

Investor Update: Exercise via Nordnet of TO1 warrants possible until October 27[th] 2022

Latest news about Brain+ A/S

Chart Brain+ A/S

Company Profile

Sector Other Software